Loading…
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $9M | $-80M | $-81M | $-82M | -29.6% | - | - |
| 2024 | $0M | $-69M | $-71M | $-52M | -22.0% | - | - |
| 2023 | $0M | $-56M | $-64M | $-38M | 36.8% | - | - |
| 2022 | $0M | $-39M | $-40M | $-36M | 35.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 8.99 |
| Operating Expense | 39.97 | 48.40 | 78.19 | 101.78 |
| Operating Income | -39.97 | -48.40 | -78.19 | -92.78 |
| EBITDA | -39.35 | -55.90 | -68.58 | -79.69 |
| EBIT | -39.48 | -56.06 | -68.74 | -79.91 |
| Pretax Income | -39.72 | -63.85 | -71.11 | -80.61 |
| Net Income | -39.72 | -63.85 | -71.11 | -80.61 |
| Net Income Common Stockholders | -39.72 | -63.85 | -71.11 | -80.61 |
| Total Expenses | 39.97 | 48.40 | 78.19 | 101.78 |
| Interest Expense | 0.24 | 7.79 | 2.37 | 0.70 |
| Interest Income | 0.47 | 2.43 | 9.63 | 13.09 |
| Research And Development | 30.52 | 33.89 | 59.04 | 73.97 |
| Selling General And Administration | 9.45 | 14.51 | 19.16 | 27.81 |
| Normalized EBITDA | -39.38 | -45.81 | -68.40 | -79.48 |
| Normalized Income | -39.74 | -53.76 | -70.93 | -80.39 |
| Basic EPS | -23.76 | -3.17 | -6.63 | 0 |
| Diluted EPS | -23.76 | -3.17 | -6.63 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0.02 | -10.09 | -0.18 | -0.21 |
| Total Unusual Items Excluding Goodwill | 0.02 | -10.09 | -0.18 | -0.21 |
| Net Income From Continuing Operation Net Minority Interest | -39.72 | -63.85 | -71.11 | -80.61 |
| Reconciled Depreciation | 0.13 | 0.16 | 0.17 | 0.21 |
| Net Interest Income | 0.22 | -5.36 | 7.26 | 12.39 |
| Net Income From Continuing And Discontinued Operation | -39.72 | -63.85 | -71.11 | -80.61 |
| Total Operating Income As Reported | -39.97 | -48.40 | -78.19 | -92.78 |
| Diluted Average Shares | 1.67 | 20.12 | 10.73 | 0 |
| Basic Average Shares | 1.67 | 20.12 | 10.73 | 0 |
| Diluted NI Availto Com Stockholders | -39.72 | -63.85 | -71.11 | -80.61 |
| Net Income Including Noncontrolling Interests | -39.72 | -63.85 | -71.11 | -80.61 |
| Net Income Continuous Operations | -39.72 | -63.85 | -71.11 | -80.61 |
| Other Income Expense | 0.02 | -10.09 | -0.18 | -0.21 |
| Special Income Charges | 0 | 0 | -0.25 | 0 |
| Other Special Charges | 0 | 0 | 0.25 | 0 |
| Gain On Sale Of Security | 0.02 | -10.09 | 0.07 | -0.21 |
| Net Non Operating Interest Income Expense | 0.22 | -5.36 | 7.26 | 12.39 |
| Interest Expense Non Operating | 0.24 | 7.79 | 2.37 | 0.70 |
| Interest Income Non Operating | 0.47 | 2.43 | 9.63 | 13.09 |
| General And Administrative Expense | 9.45 | 14.51 | 19.16 | 27.81 |
| Other Gand A | 9.45 | 14.51 | 19.16 | 27.81 |
| Operating Revenue | 0 | 0 | 0 | 8.99 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| BioAge Labs, Inc.this co. | BIOA | $749M | - | 2.32 | -29.6% | -5.11 |
| Nutex Health Inc. | NUTX | $781M | 10.68 | 2.41 | 16.7% | 2.52 |
| U.S. Physical Therapy, Inc. | USPH | $780M | 74.22 | 2.35 | 3.2% | 12.74 |
| ARS Pharmaceuticals, Inc. | SPRY | $778M | - | 6.81 | -149.9% | -3.94 |
| Castle Biosciences, Inc. | CSTL | $734M | - |
| 1.53 |
| -5.1% |
| -224.72 |
| Absci Corporation | ABSI | $732M | - | 3.77 | -60.8% | -5.15 |
| CBLL | CBLL | $729M | - | 4.65 | -34.4% | -10.30 |
| Allogene Therapeutics, Inc. | ALLO | $726M | - | 1.65 | -65.3% | -1.79 |
| Gyre Therapeutics, Inc. | GYRE | $713M | 367.50 | 6.33 | 3.5% | 46.81 |
| Peer Median | - | 74.22 | 3.09 | -19.8% | -2.86 | |